Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Oxford Nanopore Technologies Plc | LSE:ONT | London | Ordinary Share | GB00BP6S8Z30 | ORD GBP0.0001 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -0.50 | -0.41% | 121.90 | 147,334 | 11:18:58 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 121.90 | 122.40 | 124.50 | 120.80 | 124.50 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Coml Physical, Biologcl Resh | 169.67M | -154.51M | -0.1641 | -7.43 | 1.15B |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 11:32:31 | O | 715 | 121.976 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 12/11/2024 | 16:00 | UK RNS | Oxford Nanopore Technologies plc Share Incentive Plan - Director/PDMR.. |
| 11/11/2024 | 10:54 | ALNC |  Oxford Nanopore announces new executives in its leadership team |
| 11/11/2024 | 07:00 | UK RNS | Oxford Nanopore Technologies plc Changes to the senior leadership team |
| 06/11/2024 | 07:00 | UK RNS | Oxford Nanopore Technologies plc Approval of the transfer of listing.. |
| 04/11/2024 | 09:00 | UK RNS | Oxford Nanopore Technologies plc Holding(s) in Company |
| 01/11/2024 | 16:00 | UK RNS | Oxford Nanopore Technologies plc Issue of Capital and Total Voting Rights |
| 16/10/2024 | 11:00 | UK RNS | Oxford Nanopore Technologies plc Founder LTIP - Director/PDMR Notification |
| 15/10/2024 | 07:00 | UK RNS | Oxford Nanopore Technologies plc Holding(s) in Company |
| 15/10/2024 | 06:00 | UK RNS | Oxford Nanopore Technologies plc Issue of Equity and Total Voting Rights |
| 14/10/2024 | 09:00 | UK RNS | Oxford Nanopore Technologies plc Admission to Trading on the London Stock.. |
Oxford Nanopore Technolo... (ONT) Share Charts1 Year Oxford Nanopore Technolo... Chart |
|
1 Month Oxford Nanopore Technolo... Chart |
Intraday Oxford Nanopore Technolo... Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 20/11/2024 | 22:13 | OXFORD NANOPORE | 1,730 |
| 10/5/2004 | 08:41 | Ј8m boost for Online Travel | 473 |
| 29/1/2004 | 21:48 | Online Travel - Superb chart and fundamentals | 3 |
| 19/12/2003 | 17:11 | ONT - 4 new contracts worth Ј7million | 310 |
| 15/10/2003 | 02:30 | Online Travel Corporation | 962 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 11:32:31 | 121.98 | 715 | 872.13 | O |
| 11:31:21 | 122.00 | 859 | 1,047.98 | O |
| 11:28:33 | 121.90 | 72 | 87.77 | AT |
| 11:18:58 | 121.90 | 1,800 | 2,194.20 | AT |
| 11:16:18 | 121.70 | 95 | 115.62 | O |
| Top Posts |
|---|
Posted at 21/11/2024 08:20 by Oxford Nanopore Technolo... Daily Update Oxford Nanopore Technologies Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker ONT. The last closing price for Oxford Nanopore Technolo... was 122.40p.Oxford Nanopore Technolo... currently has 941,455,189 shares in issue. The market capitalisation of Oxford Nanopore Technolo... is £1,147,633,875. Oxford Nanopore Technolo... has a price to earnings ratio (PE ratio) of -7.43. This morning ONT shares opened at 124.50p |
Posted at 11/11/2024 07:27 by bamboo2 Confirmation.11 November 2024 Oxford Nanopore Technologies plc ("Oxford Nanopore" or the "Company") Oxford Nanopore announces changes to the senior leadership team Oxford Nanopore Technologies plc (LSE: ONT), the company delivering a new generation of nanopore-based molecular sensing technology, today announces that Rosemary Sinclair Dokos has been appointed as Chief Product and Marketing Officer and Dr Lakmal Jayasinghe has been appointed as Chief Scientific Officer, effective immediately. Rosemary and Lakmal, who will report to Chief Executive Officer Dr Gordon Sanghera, succeed Clive Brown, Chief Officer of Technology, Innovation, and Products, who has stepped down to pursue new projects. Clive will be available to the business on an advisory basis to support an effective transition. Rosemary has more than 18 years' experience in innovation, including product management and commercial functions. She joined Oxford Nanopore in 2014 and has been a pivotal force in driving the Company's product strategy and execution, overseeing the development of Oxford Nanopore's platform technologies, including the recent PromethION 2 and GridION Q-Line launches. In her new role, Rosemary will continue leading the development of products that include new multiomic, clinical, biopharma and industrial applications, in addition to platform technology innovations and marketing. Lakmal is a highly respected, world-leading nanopore and protein sensing scientist and scientific leader, with more than 18 years' experience. He joined Oxford Nanopore in 2007 and has been responsible for all biological research and development projects at Oxford Nanopore. Lakmal will continue to lead efforts to integrate new multiomic capabilities, including genomics, transcriptomics, proteomics, and metabolomics, into the Company's platform. Dr Gordon Sanghera, Chief Executive Officer of Oxford Nanopore, commented: "Rosemary and Lakmal have played an integral role in the research, development and execution of our technology vision for many years. They bring extensive skills in innovation and product development, and the leadership of highly skilled technical teams. These span the most cutting-edge innovation to the deployment of mature products destined for regulated markets - critical to creating stakeholder value. Their knowledge, perspective and vision will advance our innovation leadership and fuel the continuation of our growth journey. "I would like to thank Clive for his profound contributions to the development of the technology and the growth of the business over the past 16 years. He established the Company's distinct vision of distributed, accessible sequencing and fostered a culture of cutting-edge innovation and relentless pursuit of pushing technological boundaries, which has shaped Oxford Nanopore into the innovative force it is today. We continue to deliver against this vision and will carry forward his drive to deploy big ideas and solve big problems." Clive Brown, former Chief Officer of Technology, Innovation, and Products at Oxford Nanopore, commented: "It has been a privilege to work alongside Gordon, Spike and the leadership team and I am proud of all that we have achieved over the last 16 years. Given our progress, I am now pursuing my next professional challenge. Rosemary's focus on transformative product experiences and Lakmal's pioneering work in multiomics put the Company in a strong position for the next phase of its development. I would particularly like to thank the user community, who continue to work so hard to help us improve and innovate the technology to enable them to perform breakthrough science. I remain a dedicated shareholder and look forward to seeing the Company continue to go from strength to strength." |
Posted at 21/10/2024 10:12 by bamboo2 Results from new benchmarking of ONT's R10.4.1 MinION flow cells better than Illumina.This study presents a comprehensive benchmarking of variant calling accuracy in bacterial genomes using Oxford Nanopore Technologies (ONT) sequencing data. We evaluated three ONT basecalling models and both simplex (single-strand) and duplex (dual-strand) read types across 14 diverse bacterial species. Our findings reveal that deep learning-based variant callers, particularly Clair3 and DeepVariant, significantly outperform traditional methods and even exceed the accuracy of Illumina sequencing, especially when applied to ONT’s super-high accuracy model. ONT’s superior performance is attributed to its ability to overcome Illumina’s errors, which often arise from difficulties in aligning reads in repetitive and variant-dense genomic regions. |
Posted at 12/10/2024 12:45 by takeiteasy PACB up 27pc late last week - their share price analyst target is many times the current share price showing just how much the sector fell out favourWould ONT have been competing against PACB for the contract PACB announced that got the share price response?nai etc |
Posted at 11/10/2024 07:48 by bamboo2 09 October 202420 years of Nature Methods: how some papers shaped science and careers Section 7 Direct to RNA with nanopores DNA is quite hardy, so if it’s left out on a bench, it can still be analyzed. RNA, on the other hand, is best kept in a minus –80 °C freezer, says Libby Snell, an RNA biologist at Oxford Nanopore Technologies (ONT). RNases that degrade RNA are everywhere, and thus, when working with RNA, “you have to be very meticulous,” says Snell, who co-developed direct nanopore-based RNA sequencing (RNA-seq)12. A peek at ONT’s RNA lab reveals how fastidious Snell’s team is about clean surfaces and pipettes. RNA has long held her interest, given how it informs on events in a cell or organism. ONT application scientist Daniel Garalde, the paper’s first author, calls the work “one of the highlights of my career.” RNA sequencing long involved a proxy: analysis of cDNA, which requires an extra step of reverse transcribing RNAs into complementary DNA sequences. This changed with the advent of direct RNA sequencing using nanopore sequencer arrays, developed at ONT. Snell enjoys seeing the many ways the method is being used. Its potential reaches to RNA modification analysis and perhaps mRNA vaccine quality control. “I’m really proud of it and I have a framed copy of the Nature Methods cover on my wall,” says Daniel Turner. Daniel Turner, the paper’s last author, used to be at ONT and is now chief scientific officer at Cambridge, UK–based Enhanc3D Genomics. The idea of direct RNA sequencing was, he says, ambitious and challenging. The direct RNA-sequencing project helped to shape his career. Moreover, he says, “it’s not easy to figure out the potential value of something that just doesn’t exist,” and he appreciates how the company had “faith in the vision.” Turner says of the paper12, “I’m really proud of it and I have a framed copy of the Nature Methods cover on my wall.” Garalde, who co-developed direct nanopore RNA sequencing, now works in ONT’s business division in California with a focus on emerging techniques. He had joined ONT with a background in computer engineering from the University of California, Santa Cruz. He considered a postdoctoral fellowship with Hagan Bayley at the University of Oxford, one of ONT’s founders, but decided to join the company instead. In nanopore sequencing, a polynucleotide moves through a nanopore that spans a membrane in a volume of salt buffer. The readout is an electrical signal that provides information about what just traveled through the nanopore. Software converts the signal to a base sequence. Working on RNA meant re-engineering much of the technology used to sequence DNA, says Garalde. The voltage that runs across the nanopore accelerates the passage of DNA through the nanopore. Garalde and his colleagues worked on ways to slow this down, but the helicases that work with DNA didn’t work with RNA. They needed to get an RNA signal readout in the sensors. After Garalde left for California, Snell led next versions of the direct RNA sequencing chemistry up to the latest release. “It’s just tremendously better,” Garalde says. The team developed the method’s aspects in parallel, says Turner. For library prep, they worked on affixing adapters to RNA so that the nanopores would process it; they needed to assure RNA didn’t degrade in the flow cell; the right motor protein had to control the speed with which RNA passes through the nanopore; and they sought a signal readout and software for base-calling. The sequencers were not as accurate and fast as they are today, he says, but the sequencing hardware itself—the MinION sequencer—exis In Snell’s academic training at the Universities of Oxford and Reading, she used cDNA sequencing to study ancient cell lineages and the relatedness of organisms in the eukaryotic tree of life. She was intrigued about working in industry when she came across ONT, then a startup. Its long-read DNA sequencing promised to avoid needing to put together genome assemblies piecemeal from short DNA sequences. She also knew that it would be good to avoid the use of reverse transcriptases and polymerases to make cDNA, which can bias sequencing. Among the challenges with RNA, says Snell, were finding ways to keep RNA molecules intact. The work on direct RNA sequencing began around 2013 and the paper was published in 2018. At the time, it was not yet clear how scientists might apply the method but, says Snell, “I was always super excited by it,” she says. Projects like her academic ones would benefit greatly from such a capability. The team hoped the same motor protein that threads the DNA molecule through the nanopore would work for RNA. But a DNA-specific motor protein disengages from RNA, she says. After screening a variety of motor proteins, they decided on a motor protein called M1. The one they now use, M2, is RNA specific, says Snell. It does not work on DNA, just as the DNA one does not work for RNA. They explored pore modifications, too. They would set up flow cells and then wait. “Sometimes it would work and sometimes it wouldn’t,&rdqu Turner enjoys the fact that no other technology can sequence RNA directly and that a cDNA step is no longer needed with nanopore sequencing. One “gets so much closer to the action,” he says: actual RNA strands from the organism touch the nanopores during sequencing. Currently, says Snell, the nanopore sequencers read RNA at 120 nucleotides per second with a pore optimized for RNA and the RNA-specific motor protein. “We’re at about 98.8% accuracy.” When training researchers, she relishes how excited they are to sequence RNA directly. It’s normal to her, but “it’s still pretty amazing, right?” |
Posted at 30/9/2024 10:49 by shared24 Thanks Brucie for sharing your thoughts. I hope everything aligns for the expected share price growth and everyone is rewarded for their patience.Is there a share price limit ONT should hit after next week for FTSE 250 inclusion? Or does it have the market cap already for it to be considered next week after the takeover protection ends? |
Posted at 30/9/2024 09:21 by brucie5 Shared, I'm not the expert on this board and there are so many moving parts. But my feeling is that so long as they manage to maintain the growth in revenues towards 2027 and there is no disruption to the unfolding story, the share price will simply continue to progress back in the direction that it has fallen until it's taken out. £2 is the immediate hurdle; thereafter, it might spend some time ranging around the zone of £2-3, bearing in mind that it spent 18 months there on the way down. So you might need to be patient for that £6.90, though revenue growth at 30% with improving margins might be expected to have a compounding effect on the share price, no? |
Posted at 08/9/2024 12:01 by brucie5 Keyno, far be it from to disagree with the world's most successful investor, but in reality, most of the shares in my portfolio, which are all, except ONT, suppliers of generous dividends, have moving parts or are subject to variables, such that I cannot claim to understand. Recall that whenever you buy a share you are effectively betting against the market and whatever they know that you may not; nevertheless you decided to take the plunge because that is part and parcel of why we're here. But you know you may be wrong and the market right; and it is always difficult to escape some degree of confirmation bias.As for ONT, I have never claimed to understand in any real depth, though I have read as much as I can get my head round, a lot of it thanks to Bamboo, btw; and I also understand something of the competitive landscape (eg. Illumina) as well as the rapidly unfolding knowledge and usefulness of genomic testing and understanding. But even so, my understanding of the above is still rudimentary, so I have to draw my sense of what it might be worth from secondary evidence: 1. I have been interested in the IPO portfolio for some time, as well as in and out of the share itself; ONT is, or has been up to now, of course the diamond in their crown and their largest holding 2. What large life science companies are willing to shell out for it (such as bM/Novo) 3. Balance sheet, such as there is no current or imminent cash crisis 4. What the chart suggests about where it's going. I always watch out for bottoms (!) and then the consequent shape of recovery. As my posting record suggests, I have limited patience with shares that go nowhere - unless they pay a good dividend for waiting. So my repurchase here is based on my sense that there a new momentum consequent on the recent basing pattern and move back above the 200sma. Naturally, this is never a sure signal and all sorts of things might happen to reverse that. Everything is based on a balance of risk/reward, as well as past experience of how such things work out. And I am often wrong! Edit: I'd also add a further ingredient to my interest here: which is the research community that has grown up around the ONT technology. This is included in their recent report, viz- "Approximately 1,400 peer-reviewed research papers published by users of Oxford Nanopore technology in H1 2024, bringing the total to approximately 12,500 to date, showcasing breakthrough research across cancer, human genetics and infectious disease and demonstrating continued opportunity for growth in the genomics research market." It may be a strained analogy, but it reminds me somewhat of the success of the Games Workshop off the back of its Warhammer Community; the users of Nano's tech are not passive consumers of carpets, commodities, gaskets or houses; they are actively at work engaging with with the product, adding knowledge and value to the proposition; both highly educated and motivated within their field of Life Sciences. Moreover, I'm inclined to think that the huge scope of genomics across different subject divisions is likely to be synergistic, as indeed is the case within the universe of Life Sciences itself, where knowledge about gut bacteria can have material implications for everything from immunological disorders, to cancer and obesity and even to dementia risk. Finally, you might infer from this a further confirmation bias which I also readily acknowledge as possibly the most dangerous one: I really want this company to succeed! So noone should take my enthusiasm for any kind of advice. |
Posted at 03/9/2024 06:49 by bamboo2 03 September 2024Oxford Nanopore Technologies plc Interim results for the six months ended 30 June 2024 Solid underlying growth despite end-market headwinds; new customer wins and continued commercial momentum support reaffirmation of full year guidance Oxford Nanopore Technologies plc (LSE: ONT) ("Oxford Nanopore" or the "Group"), the company behind a new generation of molecular sensing technology based on nanopores, today announces its interim results for the six months ended 30 June 2024. Gordon Sanghera, Chief Executive Officer, commented: "Against a challenging backdrop, our financial and operational performance in the first half was solid and in-line with our expectations, underpinning confidence in full year guidance. We delivered robust underlying revenue growth of 12.4% constant currency and margin expansion of 120bps. "We continued with our high pace of innovation in the first half, with new product launches and platform enhancements. For example, we delivered the two product launches aimed at our regulated customer base, GridION Q-Line and Early Access of ElysION, our fully automated samples to answer product. These meet customer needs for routine, end-to-end analyses, for example in clinical and applied industrial markets, particularly with Biopharma customers. "As we look forward, our highly differentiated platform and substantial market opportunity position us well to deliver long-term, sustainable growth. Our growth and margin guidance for the full year remains unchanged. We enter the second half in a strong position; new and enlarged contract wins, such as PRECISE and Plasmidsaurus, coupled with the increased productivity of our sales teams in the second quarter reinforces our confidence in delivering between 20 - 30% underlying revenue growth on a constant currency basis in full year 2024." H1 Financial highlights · Revenue of £84.1million was broadly flat at constant currency (CC), down 2.2% on a reported basis, in-line with expectations. · Underlying revenue, excluding an £8.9 million combined headwind from COVID sequencing and the Emirati Genome Program (EGP); increased by 12.4% CC. o Underlying revenue growth delivered in all regions, led by the EMEAI and APAC, with underlying growth of 16.4% and 10.6% respectively. o Underlying revenue grew fastest across the PromethION product range[1], up 39.0% in the period to £31.9 million (H1 23: £23.0 million). Underlying revenue from the MinION product range[2] declined by 10.8% to £27.8 million (H1 23: £31.1 million) which includes a currency headwind and a mix of commercial and product specific factors. Other revenues, representing kits, services revenues and other devices grew 6.4% on an underlying basis to £22.9 million (H1 23: £21.5 million). · Gross margin increased by 120 basis points (bps) to 58.8% (H1 23: 57.6%) driven by underlying margin improvements (380bps), particularly across both PromethION Flow Cell and devices, offsetting product mix (140bps) and currency (120bps) headwinds. · Adjusted EBITDA loss of £(61.6) million (H1 23: £(39.4 million); driven by increasing operational expenses, primarily the annualised impact of additional headcount as highlighted at FY23 results. Adjusted operating costs were broadly flat (+2.0%) against H2 2023, demonstrating good cost control and with EBITDA loss lower than H2 2023 (£65.6m). · Increase in loss year-on-year to £(74.7) million (H1 23: £(70.1) million). This was predominately driven by increasing operational expenses associated with the increase in headcount partly offset by a lower Founder LTIP charge of £1.0m (H1 23: £14.9 million) and a £5.5 million credit relating to the reversal of historic employers' social security tax charges (H1 23: £1.3 million). · Strong balance sheet position; cash, cash equivalents and other liquid investments of £397.1 million[3] as at 30f June 2024, compared to £472.1 million as of 31 December 2023. Post period end the Group raised net proceeds of £78.2 million, following the successful completion of a multiple times oversubscribed £80.0 million equity placing, which included a new £50.0 million strategic investment from Novo Holdings. H1 Business highlights · Continued commercial progress in the period, evidenced by improving utilisation across existing customers, leading to a growing revenue opportunity for the Group driven by the enlarged and now established commercial infrastructure. · New contract wins and contract expansions with larger PromethION devices (P24 and P48), including Precision Health Research Singapore (PRECISE), which selected Oxford Nanopore technology to sequence 10,000 long read human genomes to gain deeper insights into Asian genetic diversity, and a multi-million, multi-year contract expansion with Plasmidsaurus, to deliver high-accuracy whole plasmid sequencing with fast turnaround times. · New strategic collaborations added to develop and access new growth markets in biopharma, clinical and industrial applications, including a collaboration with Lonza on a novel test to accelerate analysis of mRNA products. · Progress was made to advance existing collaborations in H1, including with bioMérieux. A test for determining antibiotic resistance in tuberculosis is expected to be released as a research-use only product in Q4, prior to seeking IVD approvals by the end of 2025. · Early Access[4] launch of PromethION 2 Integrated (P2i) in Q2, and continued rollout of the PromethION 2 Solo (P2S), following its successful launch in 2023. Evidence of continued market traction and disruption with more than 1,350 P2 devices now in the field. The P2 devices represent a new market area of affordable, accessible and high output sequencing. · Strong progress against our 2024 innovation goals, with the launch of new products from our regulated pipeline, including GridION Q-Line and the Early Access of ElysION, our sample-to-answer automated sequencing solution, to drive adoption in new clinical and applied industrial markets. · Approximately 1,400 peer-reviewed research papers published by users of Oxford Nanopore technology in H1 2024, bringing the total to approximately 12,500 to date, showcasing breakthrough research across cancer, human genetics and infectious disease and demonstrating continued opportunity for growth in the genomics research market. · Expansion of the leadership team, to support the business in its next phase of growth: Nick Keher appointed as CFO and Director of Oxford Nanopore in January, adding significant financial leadership experience and a deep understanding of global capital markets. Nick succeeds Tim Cowper, who moves into a new role as Chief Operating Officer and will lead Oxford Nanopore's continuous improvement programmes and expanding international footprint and operations. |
Posted at 01/8/2024 06:38 by bamboo2 Oxford Nanopore attracts investment from Novo Holdings and completes Equity Issue of £80 millionOxford Nanopore announces the successful completion of the bookbuilding process for the placing of new ordinary shares of £0.0001 each in the capital of the Company ("New Ordinary Shares") announced yesterday (the "Placing"). In light of the strong demand from investors, with the transaction multiple times oversubscribed, the Board has decided to increase the size of the Equity Issue from approximately £75 million to £80 million. A total of 25,000,000 New Ordinary Shares (the "Placing Shares") have been placed by Citigroup Global Markets Limited ("Citi"), J.P. Morgan Securities plc (which conducts its UK investment banking business as J.P. Morgan Cazenove) ("J.P. Morgan Cazenove") and Joh. Berenberg, Gossler & Co. KG ("Berenberg" and, together with Citi and J.P. Morgan Cazenove, the "Joint Bookrunners") at a price of 120 pence per Placing Share (the "Placing Price") raising gross proceeds of approximately £30 million. As a result of the successful placing, the subscription by Novo Holdings A/S ("Novo Holdings") has been reduced from £60 million such that it will subscribe for 41,666,667 New Ordinary Shares (the "Subscription Shares") at the Placing Price, raising gross proceeds of approximately £50 million. Novo Holdings currently intends, subject, inter alia, to availability and price, to add over time to their initial primary investment through further market purchases of up to £10 million. Therefore, the Placing and Subscription (together, the "Equity Issue") will raise total gross proceeds of approximately £80 million. Dr. Gordon Sanghera, CEO, Oxford Nanopore said: "We are delighted to welcome this new, strategic investment from Novo Holdings, alongside continuing support from our existing investors. Over recent years, we have further iterated our technology platform and commercial infrastructure and are poised to gain further traction in broad sectors including scientific research, clinical and applied industrial markets. The investment from Novo Holdings reflects our ambition in the biopharmaceutical sector. Our technology platform is uniquely suited to address the needs of this industry where information-rich, rapid and simplified sequencing are critical to developing and delivering biopharmaceuticals faster and with less complexity. We look forward to their support." Together, the Placing Shares and Subscription Shares ("New Ordinary Shares") being issued represent approximately 8 per cent. of the issued ordinary share capital of Oxford Nanopore prior to the Equity Issue. The Placing Price of 120 pence represents a discount of approximately 0.7 per cent. to the closing share price of 120.80 pence on 31 July 2024. As per the new U.K. listing regime, applications have been made for the New Ordinary Shares to be admitted to the "transition" listing segment of the Official List (the "Official List") of the Financial Conduct Authority (the "FCA") and to be admitted to trading on the main market for listed securities of the London Stock Exchange plc (the "London Stock Exchange") (together, "Admission"). Settlement of the New Ordinary Shares and Admission are expected to take place on or around 8.00 a.m. on 5 August 2024. The Placing is conditional upon, amongst other things, Admission becoming effective and upon the placing agreement between the Joint Bookrunners and the Company not being terminated in accordance with its terms. The New Ordinary Shares, when issued, will be fully paid and will rank pari passu in all respects with each other and with the existing Ordinary Shares, including, without limitation, the right to receive all dividends and other distributions declared, made or paid after the date of issue. Following Admission, the total number of Ordinary Shares in issue in Oxford Nanopore will be 940,896,164. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of voting rights in Oxford Nanopore will be 940,896,164 following Admission, and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Oxford Nanopore under the FCA's Disclosure Guidance and Transparency Rules. Citi, J.P. Morgan Cazenove and Berenberg acted as Joint Global Coordinators, Joint Bookrunners and Joint Corporate Brokers in respect of the Placing. About Novo Holdings Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation. The purpose of Novo Holdings is to improve people's health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation. Wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk A/S and Novonesis A/S (Novozymes A/S) and manages an investment portfolio with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure and private equity assets, Novo Holdings is a world-leading life sciences investor. Through its Seed, Venture, Growth, Asia, Planetary Health and Principal Investments teams, Novo Holdings invests in life science companies at all stages of development. As of year-end 2023, Novo Holdings had total assets of €149 billion. www.novoholdings.dk |
Posted at 22/3/2024 16:53 by minsky x = ONT share price;while x > 0 { bamboo2 posts article about ONT success; x = x-2; } |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
